A Novel Ferroptosis-Related lncRNAs Signature Predicts Clinical Prognosis and Is Associated With Immune Landscape in Pancreatic Cancer.
clinical prognosis
ferroptosis
immune landscape
lncRNAs
pancreatic cancer
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
09
2021
accepted:
31
01
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Pancreatic cancer is one of the most lethal malignancies and currently therapies are severely lacking. In this study, we aimed to establish a novel ferroptosis-related lncRNAs signature to predict the prognosis of patients with pancreatic cancer and evaluate the predictive abilities of candidate lncRNAs. According to The Cancer Genome Atlas (TCGA) database, a total of 182 patients with pancreatic cancer were included in our study. Ferroptosis-related lncRNAs were screened by Pearson correlation analysis with 60 reported ferroptosis-related genes. Through univariate, least absolute shrinkage and selection operator (LASSO) regression and multivariate regression analyses, a novel signature based on five ferroptosis-related lncRNAs(
Identifiants
pubmed: 35330729
doi: 10.3389/fgene.2022.786689
pii: 786689
pmc: PMC8940287
doi:
Types de publication
Journal Article
Langues
eng
Pagination
786689Informations de copyright
Copyright © 2022 Ping, Jia and Ke.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cancer. 2021 Jan 1;12(2):387-396
pubmed: 33391435
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Eur Rev Med Pharmacol Sci. 2020 Sep;24(18):9315-9324
pubmed: 33015772
Int J Biol Sci. 2021 May 11;17(8):1979-1994
pubmed: 34131400
Nat Rev Gastroenterol Hepatol. 2009 Dec;6(12):699-708
pubmed: 19806144
Front Cell Dev Biol. 2021 Jul 07;9:698296
pubmed: 34307375
Front Cell Dev Biol. 2021 Nov 08;9:751490
pubmed: 34820377
J Cancer. 2020 Jul 20;11(19):5556-5567
pubmed: 32913451
Nature. 2019 May;569(7755):270-274
pubmed: 31043744
Cancer Cell Int. 2021 Nov 4;21(1):591
pubmed: 34736453
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581043
Lab Invest. 2018 Jun;98(6):814-824
pubmed: 29581580
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Science. 2020 Apr 3;368(6486):85-89
pubmed: 32241947
Oncotarget. 2017 Aug 18;8(48):84153-84167
pubmed: 29137412
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
pubmed: 24399786
Cancer Res. 2018 Jul 1;78(13):3484-3496
pubmed: 29588351
Nature. 2012 Feb 15;482(7385):339-46
pubmed: 22337053
Clin Cancer Res. 2017 Jun 15;23(12):3129-3138
pubmed: 28007776
Genome Res. 2020 Jul;30(7):1060-1072
pubmed: 32718982
PLoS Med. 2010 Apr 20;7(4):e1000267
pubmed: 20422030
Biochem Biophys Res Commun. 2016 May 13;473(4):775-780
pubmed: 27037021
Cancer Metastasis Rev. 2018 Mar;37(1):75-81
pubmed: 29230620
Cell Death Differ. 2016 Mar;23(3):369-79
pubmed: 26794443
Cancer Sci. 2020 Aug;111(8):3057-3070
pubmed: 32495519
J Thorac Cardiovasc Surg. 2018 Apr;155(4):1793
pubmed: 29370910
Oncoscience. 2015 May 02;2(5):517-32
pubmed: 26097885
Cancer Cell. 2017 Jun 12;31(6):848-848.e1
pubmed: 28609660
Nature. 2007 Jun 14;447(7146):864-8
pubmed: 17568748
Front Cell Dev Biol. 2021 Nov 08;9:746696
pubmed: 34820374
Cell Death Differ. 2019 Nov;26(11):2329-2343
pubmed: 30787392